| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cichoric acid Cichoric acid / Chicoric acid — Cichoric acid is a naturally occurring dicaffeoyltartaric acid polyphenol, formally a hydroxycinnamic acid derivative composed of two caffeic acid units esterified to tartaric acid. It is best classified as a plant-derived phenolic acid / caffeic-acid derivative rather than a drug. Standard abbreviations include Cic, ChicA, and CA, although CA is ambiguous because it is also used for caffeic acid, chlorogenic acid, carnosic acid, and many other database entries. Major sources include Echinacea purpurea, chicory, lettuce, basil, dandelion, and other Asteraceae/Lamiaceae plants. It is commonly used as a quality-marker compound for Echinacea purpurea extracts, but its direct cancer-development status remains preclinical only. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral systemic translation is constrained by polyphenol-type absorption, metabolism, plasma protein binding, and formulation stability. Rat PK/tissue-distribution work exists, but direct human PK data for isolated cichoric acid are limited. Echinacea extract exposure cannot be assumed to equal isolated cichoric acid exposure because alkamides, polysaccharides, glycoproteins, caftaric acid, and other constituents may drive part of the immune effect. In-vitro vs systemic exposure relevance: Many mechanistic studies use low-to-high micromolar cichoric acid concentrations. These concentrations may exceed free systemic exposure achievable from ordinary oral Echinacea or food intake, especially after first-pass and microbial metabolism. Low-micromolar effects such as 5 μM otoprotection in zebrafish are more pharmacologically plausible than high-micromolar cytotoxicity screens, but human-equivalent exposure remains uncertain. Clinical evidence status: Cancer: preclinical only; no adequate human cancer trials for isolated cichoric acid. Immune / respiratory use: human evidence exists for Echinacea preparations, but not as isolated cichoric acid attribution. Alzheimer’s disease: preclinical only, with cell and animal-model support but no validated human clinical efficacy. Regulatory/deployment status: listed as a natural-health-product ingredient name by Health Canada; not an approved anticancer or AD therapeutic. Cichoric Acid Mechanistic Profile
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr Alzheimer’s disease relevance: Cichoric acid has meaningful AD-preclinical relevance but no validated human AD clinical evidence. The main AD rationale is neuroinflammation and amyloid-pathology modulation rather than direct symptomatic cholinergic therapy. In animal and cellular AD models, cichoric acid has been reported to reduce Aβ burden, lower APP/BACE1 markers, improve synaptic-function markers, and activate antioxidant signaling. This supports an AD database sub-entry as preclinical / experimental, not as a clinically established intervention. AD mechanisms (ranked):
Clinical evidence status: AD evidence remains preclinical. No adequate human RCT evidence supports cichoric acid as an Alzheimer’s disease treatment. Translation constraints include oral exposure, blood-brain exposure, dose standardization, and uncertainty over whether whole-plant extracts reproduce isolated cichoric acid effects. Cichoric Acid Alzheimer’s Disease Mechanistic Profile
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Lipid peroxidation is a chain reaction process in which free radicals (often reactive oxygen species, or ROS) attack lipids containing carbon-carbon double bonds, especially polyunsaturated fatty acids. This attack results in the formation of lipid radicals, peroxides, and subsequent breakdown products. Lipid peroxidation can cause damage to cell membranes, leading to increased permeability and disruption of cellular functions. This damage can initiate a cascade of events that may contribute to carcinogenesis. The byproducts of lipid peroxidation, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), can form adducts with DNA, leading to mutations. These mutations can disrupt normal cellular processes and contribute to the development of cancer. Lipid peroxidation damages cell membranes, disrupts cellular functions, and can trigger inflammatory responses. It is a marker of oxidative stress and is implicated in many chronic diseases. Negative Prognostic Indicator: In many cancers, high levels of lipid phosphates, particularly S1P, are associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy. Mixed Evidence: The prognostic significance of lipid phosphates can vary by cancer type, with some studies showing that their expression may not always correlate with adverse outcomes. |
| 6623- | Cic, | MTX, | Chicoric acid prevents methotrexate hepatotoxicity via attenuation of oxidative stress and inflammation and up-regulation of PPARγ and Nrf2/HO-1 signaling |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:416 Target#:453 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid